Tirzepatide vs Liraglutide
Side-by-Side Comparison
| Attribute | Tirzepatide | Liraglutide |
|---|---|---|
| Category | Metabolic / Dual GIP-GLP-1 Agonist | Metabolic / GLP-1 Agonist |
| Mechanism | Tirzepatide (MW ~4813 g/mol, C225H348N48O68) simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. | Liraglutide binds to GLP-1 receptors on pancreatic β-cells, increasing intracellular cAMP and triggering glucose-dependent insulin secretion. |
| Evidence Rating | A — FDA Approved | A — FDA Approved |
| Clinical Status | FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA) | FDA-approved (Victoza for T2D, Saxenda for obesity) |
| Safety Profile | Common (5%+ in trials): abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, GERD, hair loss, hypersensitivity reactions, injection site reactions, nausea, vomiting; Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems | Common: nausea (39%), diarrhea (21%), constipation (19%), vomiting (15%), headache (13%); GI side effects are dose-dependent and typically diminish over weeks |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | 2.5–15 mg/week, titrated every 4 weeks | Saxenda: 0.6-3.0 mg/day; Victoza: 0.6-1.8 mg/day |
| Frequency | Once weekly | Once daily |
| Molecular Weight | ~4813.5 g/mol | ~3,751 g/mol |
| Half-Life | ~5 days (116 hours) | ~13 hours |
Overview
Tirzepatide and Liraglutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Tirzepatide — Mechanism & Evidence
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly, FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) including severe obstructive sleep apnea in adults with obesity. It is a 39-amino-acid peptide with a C20 fatty di-acid moiety that promotes albumin binding, enabling once-weekly dosing. Clinical trials consistently demonstrate it delivers the most substantial weight reduction among incretin-based therapies, with up to 22.5% mean body weight loss at 72 weeks.
Key claims: Superior weight loss compared to semaglutide; Improves blood sugar control; May improve liver fat / NASH.
Liraglutide — Mechanism & Evidence
Liraglutide is an FDA-approved GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1. Developed by Novo Nordisk, it is approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was the first GLP-1 agonist approved for obesity. While effective, it has been largely superseded by semaglutide (once-weekly dosing, greater weight loss) — liraglutide requires daily injection and achieves approximately 8% weight loss vs semaglutide's 15%.
Key claims: Clinically significant weight loss; Improves glycemic control; Cardiovascular benefit.
Shared Research Applications
Both peptides are studied for: Weight Management, Metabolic Health.
Tirzepatide is also researched for: no additional unique applications.
Liraglutide is also researched for: Cardiovascular.
Safety Considerations
Tirzepatide: Common (5%+ in trials): abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, GERD, hair loss, hypersensitivity reactions, injection site reactions, nausea, vomiting Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems FDA boxed warning for thyroid C-cell tumors (rodent data); call doctor for neck lump, swallowing difficulty, hoarseness, or shortness of breath
Liraglutide: Common: nausea (39%), diarrhea (21%), constipation (19%), vomiting (15%), headache (13%) GI side effects are dose-dependent and typically diminish over weeks FDA black box warning for thyroid C-cell tumors (rodent data)
Related Products
Tirzepatide 10mg
10mg
Related Research News
Is Tirzepatide Better Than Semaglutide for Weight Loss? Comparison
A comparison examines if Tirzepatide outperforms Semaglutide for weight loss. The two drugs are directly contrasted on this measure. This regulatory news covers the key question of superiority.
Daily Orforglipron Preserves Weight Loss After Semaglutide or Tirzepatide
Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide. The medication supports maintenance of weight reduced during prior use of these treatments. Its once-a-day schedule aids in sustaining results from semaglutide or tirzepatide therapy.
FDA Proposes Ban on Bulk Compounding of Semaglutide and Tirzepatide
The U.S. Food and Drug Administration has proposed a ban on bulk compounding of semaglutide and tirzepatide. This regulatory proposal names semaglutide and tirzepatide as the drugs subject to the ban. The action focuses on prohibiting bulk compounding for these two medications.